Arkin ramping up investments with $140M fund

Arkin Holdings closed its second biopharma fund Monday at $140 million, more than double its debut fund, which launched with $60 million in 2016 and was fully committed at the end of 2019.

As with its first fund, the firm will focus on investing in companies in the U.S., EU and Israel developing cancer, rare disease, RNA and gene therapies. ...